share_log

Analysts Rally Behind Waystar: Predict Robust Growth and Market Share Gains Following Competitor Setback

Analysts Rally Behind Waystar: Predict Robust Growth and Market Share Gains Following Competitor Setback

分析師們力挺Waystar:預測競爭對手挫敗後將獲得強勁的增長和市場份額提升。
Benzinga ·  02:05

BofA Securities analyst Allen Lutz initiated coverage on Waystar Holding Corp. (NASDAQ:WAY) with a Buy rating and price forecast of $27.

BofA Securities分析師Allen Lutz發表評論,將Waystar Holding Corp. (NASDAQ:WAY)評級爲“買入”,目標價爲27美元。

According to Lutz, Waystar is well positioned for 10% revenue growth supported by steady end-market demand and recent competitive changes.

根據Lutz的說法,Waystar因市場需求穩定和近期競爭變化的支持而處於良好位置,將實現10%的營收增長。

In addition, the cybersecurity attack on competitor Change Healthcare could drive Waystar's market share gains.

此外,Change Healthcare的網絡安全攻擊可能會推動Waystar的市場份額增長。

In response to the Change disruption in February, Waystar launched a program for impacted providers to expedite access to its platform within 2-3 days of contract execution.

針對2月份發生的Change干擾,Waystar推出了一個計劃,以便受影響的提供商在合同簽訂後2-3天內快速訪問其平台。

The company initially added 30K provider customers and could add more over the next few quarters, the analyst adds.

分析師補充道,公司最初增加了3萬個服務商客戶,未來幾個季度可能會增加更多客戶。

Waystar operates in a $15 billion market, with stable ~40% margins over the next three years. Precisely, the company has a solid opportunity to expand its existing relationships with 18 of the top 22 hospitals and potential changes in the competitive environment can support further growth.

Waystar在150億美元的市場中運營,在未來三年內有着穩定的40%利潤率。公司與前22家醫院中的18家已經建立了很好的關係,未來的競爭環境變化有助於進一步增長。

Over time, Lutz projects a structural shift in health systems, reducing dependence on Change by diversifying with independent vendors to guard against future cyber breaches. The analyst projects FY24 EPS of $0.20.

隨着時間的推移,Lutz預計衛生系統將出現結構性轉變,通過與獨立供應商組合減少對Change的依賴,以防止未來的網絡安全漏洞。分析師預測FY24每股收益爲0.20美元。

Goldman Sachs analyst Adam Hotchkiss initiated coverage on Waystar with a Buy rating and a $32 price forecast.

高盛分析師Adam Hotchkiss將Waystar評級爲“買入”,目標價爲32美元。

Per Hotchkiss, Waystar's comprehensive technology platform, addressing multiple points across the healthcare revenue cycle, is unique within a market dominated by point-solution technology vendors, manual processes, and healthcare IT services businesses.

Hotchkiss指出,Waystar的全面技術平台,在衛生保健收入週期的多個關鍵點進行了解決,這在由點解決方案技術供應商、手動流程和衛生保健IT服務企業主導的市場中是獨一無二的。

The analyst adds that Waystar's deliberate combination of assets drives a more compelling sale to and partnership with larger hospitals and health systems. The analyst projects FY24 EPS of $0.21.

分析師補充道,Waystar的資產有意地結合起來,向大型醫院和衛生系統提出了更具吸引力的銷售和合作。分析師預測FY24每股收益爲0.21美元。

William Blair analyst Ryan Daniels initiates coverage on Waystar Holding with an Outperform rating.

William Blair分析師Ryan Daniels將Waystar Holding評級爲“跑贏大盤”(Outperform)。

For fiscal 2024, the analyst projects total revenue of $885 million, adjusted EBITDA of $351 million, and adjusted earnings per share of $0.19.

對於2024財年,分析師預計總收入爲8.85億美元,調整後的EBITDA爲3.51億美元,調整後的每股收益爲0.19美元。

For fiscal 2025, Daniels projects revenue of $971 million, adjusted EBITDA of $380 million, and adjusted earnings per share of $0.69.

對於2025財年,Daniels預計收入爲9.71億美元,調整後的EBITDA爲3.8億美元,調整後的每股收益爲0.69美元。

Price Action: WAY shares are trading higher by 0.46% to $21.61 at last check Tuesday.

股票價格行情:在上週二最後一次檢查時,WAY股票價格上漲了0.46%,達到21.61美元。

Image via Dall-E 3

圖像通過Dall-E 3

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論